Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02354703 · ClinicalTrials.gov registry record · Phase 2
Pharmacogenetic Study of Ondansetron in Alcohol Use Disorder
A Phase 2 study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Phase 2
- Development phase
- 293
- Enrollment target
NCT02354703 is a Phase 2 study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 293 participants.
The verdict
NCT02354703, a Phase 2 study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 293 participants
- Enrollment target
Study Summary
The primary study objective is to determine the efficacy of ondansetron (0.33 mg twice daily) administered orally for a period of 16 weeks in reducing risky drinking among currently drinking subjects with alcohol use disorder who have selected genotypes at the serotonin transporter and receptor genes. The secondary objective is to assess the safety and tolerability of ondansetron in subjects with alcohol use disorder who have selected genotypes at the serotonin transporter and receptor genes.
Interventions
- DRUG Placebo
- DRUG Ondansetron
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 293 participants |
| Start Date | 2015-08 |
| Est. Completion | 2020-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02354703
The ClinicalTrials.gov registry entry for NCT02354703 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 293 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02354703 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02354703 about?
NCT02354703 is a clinical study titled "Pharmacogenetic Study of Ondansetron in Alcohol Use Disorder". The primary study objective is to determine the efficacy of ondansetron (0.33 mg twice daily) administered orally for a period of 16 weeks in reducing risky drinking among currently drinking subjects with alcohol use disorder who have selected genotypes at the serotonin transporter and receptor gene...
What is the current status of trial NCT02354703?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 293 participants. The study started on 2015-08. Estimated completion is 2020-03-31.
What interventions are being tested in trial NCT02354703?
The interventions under investigation include: Placebo (DRUG), Ondansetron (DRUG).
Who is sponsoring clinical trial NCT02354703?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.